TCTMD: Dapagliflozin Boosts Health Status Across LVEF Range

Dapagliflozin improves symptoms and physical limitations in people with heart failure across the spectrum of ejection fractions, according to a pooled analysis of the DEFINE-HF and PRESERVED-HF trials.

“The effects were large, clinically meaningful, and statistically significant,” said Mikhail Kosiborod, MD (Saint Luke’s Mid America Heart Institute, Kansas City, MO), who presented the results Sunday at the European Society of Cardiology 2022 Heart Failure congress. “Collectively, these results provide support for the use of dapagliflozin in patients with heart failure, regardless of ejection fraction.”

Speaking with TCTMD, Kosiborod stressed that trials in heart failure patients with reduced ejection fraction (HFrEF) have shown that dapagliflozin (Farxiga; AstraZeneca), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduces the risk of cardiovascular deaths and hospitalizations while improving health status and quality of life. For patients with HF and preserved ejection fraction (HFpEF), however, “the picture has been a little bit less consistent,” he acknowledged.

Read the full TCTMD article: Dapagliflozin Boosts Health Status Across LVEF Range

Related Content

Saint Luke's Mid America Heart Institute
Oct. 28, 2021
PRESERVED-HF trial findings on the substantial impact of dapagliflozin in individuals with heart failure with preserved ejection fraction (HFpEF) published in Nature Medicine
The findings of the PRESERVED-HF trial, offering potential new hope for people struggling with heart failure with preserved ejection fraction (HFpEF), are published in the journal, Nature Medicine.
Sep. 17, 2021
Healio: PRESERVED-HF: Dapagliflozin improves HFpEF symptoms at 12 weeks
Dapagliflozin improved symptoms and physical limitations in patients with heart failure (HF) with preserved ejection fraction, according to results from the PRESERVED-HF trial.
hand holding heart-shaped pill
Sep. 17, 2019
TCTMD: DEFINE-HF: Dapagliflozin Improves Function and Quality of Life, but Not Biomarkers, in HFrEF
A new study championed by Saint Luke's, called DEFINE-HF, was recently presented at the Heart Failure Society of America annual meeting. tctMD breaks down this groundbreaking study of the new treatment option with study chair Mikhail Kosiborod, MD.